Opus Genetics IRD Noncash Or Part Noncash Acquisition Value Of Liabilities Assumed1
Noncash Or Part Noncash Acquisition Value Of Liabilities Assumed1 at other companies
Other financials
Where this comes from
Reported directly by Opus Genetics in its filing.
Tagged under the XBRL concept us-gaap:NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1.
The official record: Opus Genetics’s 10-K, filed March 12, 2026, on SEC EDGAR. View the filing →
Ask your AI about Opus Genetics's noncash or part noncash acquisition value of liabilities assumed1.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Opus Genetics's noncash or part noncash acquisition value of liabilities assumed1?
- Opus Genetics (IRD) reported noncash or part noncash acquisition value of liabilities assumed1 of $0 in Q4 2025.
- How has Opus Genetics's noncash or part noncash acquisition value of liabilities assumed1 changed year-over-year?
- Opus Genetics's noncash or part noncash acquisition value of liabilities assumed1 decreased by 100.0% year-over-year, from $238.75K to $0.
- What does noncash or part noncash acquisition value of liabilities assumed1 mean?
- Represents the value of liabilities assumed by the company as part of an acquisition or business combination that did not involve an immediate cash outlay. Tracking this helps investors understand the total consideration paid for an acquisition beyond the cash purchase price.